8 results about "Artesunate" patented technology

This invention discloses a butyrate prodrug co-assembled with artesunate, its preparation method, and its application in kidney diseases, belonging to the field of biomedical technology. The invention first uses docosahexaenoic acid (DHA) as a hydrophobic framework, coupling it with 2,2'-dithiodiethanol to introduce disulfide bonds, and then grafts butyrate via esterification to obtain a butyrate prodrug. The butyrate prodrug and artesunate self-assemble through non-covalent interactions to obtain a co-assembled drug in nanoparticle form. This nanomedicine possesses excellent long-term in vivo circulation and passive targeted accumulation in the kidneys, and can achieve targeted drug release in response to the high-glutathione microenvironment within lesion cells. The two active ingredients synergistically exert metabolic regulation, anti-inflammatory, and antioxidant effects, inhibiting kidney inflammation and oxidative stress at multiple targets, protecting renal tubular epithelial cells, and effectively intervening in the pathological process of acute kidney injury. Furthermore, this drug has high biosafety, is simple to prepare, and is easy to scale up, showing broad application prospects in the prevention and treatment of kidney diseases.

This application discloses the use of artesunate in the preparation of drugs for enhancing the therapeutic effect of PARP inhibitors, belonging to the field of biomedical technology. The artesunate described in this application is a sesquiterpene lactone derivative extracted from the traditional Chinese medicine Artemisia annua. It has an inhibitory effect on the proliferation of BRCA wild-type ovarian cancer cells and low toxicity to normal human ovarian epithelial cells. This application's research found that artesunate can enhance the DNA damage and apoptosis induced by PARP inhibitors (such as olaparib, niraparib, and rucaparib), and improve the sensitivity of PARP inhibitors to BRCA wild-type ovarian cancer.

The invention relates to a pharmaceutical composition in the form of a spheroid dosage form that can be absorbed by oral route, said spheroid containing, as the sole active ingredient with antimalarial activity, a therapeutically effective amount of at least 200 mg of artesunate, for use as a drug.

The invention discloses application of artesunate in preparation of a PRMT1 inhibitor and / or an alpha-ketoglutaric acid supplement, and relates to the technical field of biological medicines. It is found through experiments that artesunate can target and inhibit the activity of arginine methyltransferase of PRMT1, inhibit methylation modification of downstream molecules IDH2 of PRMT1 and reduce expression of the downstream molecules IDH2, and then mitochondrial metabolic disorder in cancer cells is induced, including accumulation of various metabolites such as alpha-ketoglutaric acid. Therefore, a new application of artesunate is provided, and artesunate is used for preparing a PRMT1 inhibitor and / or an alpha-KG supplement. In addition, it is verified that artesunate can significantly inhibit tumor growth of multiple tumor-bearing mice and promote anti-tumor immunity, and artesunate can be used as a PRMT1 inhibitor and / or an alpha-KG supplement to prepare anti-tumor immunotherapy drugs.

The invention discloses an application of artesunate in preparation of a medicine for treating ureteral fibrosis after ureteral obstruction, and finds and verifies that artesunate can inhibit ureteral fibrosis and relieve hydronephrosis in an animal model of ureteral obstruction for the first time. A new direction is provided for research and development of ureteral fibrosis treatment medicines, artesunate is expected to become a safer and more effective medicine for treating ureteral fibrosis, and the artesunate has a wide application prospect in the field of ureteral fibrosis treatment.

This invention relates to the field of medical antibacterial technology, and in particular to a rare-earth artemisinin derivative organic salt, its preparation method, and its application, with the general formula [Art-COO]. n RE n+ In the formula, Art represents an artemisinin derivative, RE represents a rare earth ion, and n represents the valence of the rare earth ion; artemisinin derivatives include artesunate, and rare earth ions include La... 3+ Ce 3+ One of them. This invention utilizes the above-mentioned rare-earth artemisinin derivative organic salt, its preparation method, and its application. The obtained organic salt retains the peroxide bridge structure of artesunate, while the carboxylate group (-COO) is present. ‑ The stable existence of coordination bonds between rare earth ions and artesunate allows rare earth ions to synergistically enhance the antibacterial effect, significantly reducing the minimum inhibitory concentration against a variety of pathogens, and thus having important application value in the field of medical anti-infection.

The invention discloses application of artesunate in preparation of medicines and health care products for preventing and treating iron-deficiency anemia caused by iron absorption disorder and / or iron transport dysfunction, in-vitro experiments find that artesunate can target divalent metal transport protein (DMT1), DMT1 is oxidized through free radicals to form disulfide bonds, the space structure of DMT1 is changed, and the iron-deficiency anemia caused by iron absorption disorder and / or iron transport dysfunction is prevented. The iron transport function of the DMT1 protein is enhanced, so that the uptake of divalent iron by cells is effectively increased; animal experiments further prove that the artesunate can remarkably improve anemia symptoms of mice with iron-deficiency anemia, anemia related indexes of the mice are effectively recovered, and the iron content in red blood cells and livers is recovered to the normal level. In-vitro and in-vivo experiments prove the treatment effect of artesunate on iron-deficiency anemia, a new treatment scheme is provided for treatment of iron-deficiency anemia patients, and the indication types of artemisinin drugs are expanded.

Use of artesunate in the preparation of a medicament for preventing and treating anemia. In vitro experiments have shown that artesunate can enhance the iron transport function of the DMT1 protein to increase iron ion uptake. In addition, animal experiments have demonstrated that artesunate can significantly improve anemia symptoms in mice with iron-deficiency anemia, effectively restore anemia-related indicators, and even restore the iron content in red blood cells and the liver to a healthy level.